

## SEMINAR OVERVIEW

This seminar series will provide updates on the latest clinical research with a strong focus on patient care. Teams of local hepatology experts (physicians and advanced practice providers) will provide an interdisciplinary approach to diagnosis and treatment in a classroom setting that stresses strong interaction between participants and faculty. Further, the interdisciplinary faculty promotes how optimal patient outcomes can be achieved through a team approach.

To lower the barriers to participation and increase access, the program will be offered on Saturdays at ten cities throughout the country beginning in February 2018. See the calendar of programs.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

**Primary Biliary Cholangitis (PBC)** is an old disease but one that is experiencing some major changes. A new treatment, Obetacholic Acid (OCA), the first new drug for the disease in 20 years, is expected to be a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

**Non-Alcoholic Steatohepatitis (NASH)** is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers to help diagnose it and follow experimental therapies. Clinical experts will provide a thorough review of non-invasive diagnostic testing and discuss several exciting new therapies being developed.

**End Stage Liver Disease (ESLD)** is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

**Hepatocellular Carcinoma (HCC)** is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies.

# 2018

**Emerging Therapies for PBC, NASH, ESLD and HCC**  
An Evidence-Based Seminar Focused on Chronic Liver Diseases

UNIVERSITY OF  
**LOUISVILLE**  
Continuing Medical Education &  
Professional Development  
University of Louisville  
Louisville, KY 40292

## LOCATIONS & FACULTY

### Louisville, Kentucky

Saturday, February 24  
University of Louisville Clinical &  
Translational Research Bldg  
**Craig McClain, MD**  
University of Louisville School of Medicine  
**Ashutosh Barve, MD, PhD**  
University of Louisville School of Medicine  
**Matthew Cave, MD**  
University of Louisville School of Medicine  
**Barbra Cave, APRN, FNP-BC**  
University of Louisville Hep C Center

### Raleigh-Durham, NC

Saturday, March 3  
Sheraton Imperial Hotel  
**Andrew Muir, MD**  
Duke University School of Medicine  
**Sidney Barritt, MD**  
University of North Carolina School of Medicine  
**Elizabeth Goacher, PA-C**  
Duke University School of Medicine

### Austin, TX

Saturday, March 10  
Hilton Austin Airport  
**Imtiaz Alam, MD**  
Austin Hepatitis Center  
**Saira Aijaz Khaderi, MD, MPH**  
Baylor College of Medicine  
**Shadi Giani, APRN, ACNS**  
Austin Hepatitis Center


### Los Angeles, CA

Saturday, March 17  
Embassy Suites – Glendale  
**Tram Tran, MD**  
Cedar Sinai Medical Center  
**Tes-Ling Fong, MD**  
University of Southern California School of Medicine  
**Lucy Mathew, ACNP-BC**  
University of Southern California School of Medicine


### Washington, DC

Saturday, April 28  
Embassy Suites – Alexandria Old Town  
**Zobair Younossi, MD**  
Inova Medical Center  
**Kirti Shetty, MD**  
John Hopkins University School of Medicine  
**Brian Lam, PA-C**  
Inova Medical Center


# Don't Miss Out On This National Program Coming To A City Near You!




Louisville, KY  
February 24




Raleigh-Durham, NC  
March 3



Austin, TX  
March 10



Los Angeles, CA  
March 17



Washington D.C.  
April 28

## PROGRAM HIGHLIGHTS

- > New content based on the latest clinical guidelines and outcomes trials developed by national experts
- > Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs
- > Interactive format that includes practical patient case review, small group discussion and the use of Audience Response technology to gauge opinion and build consensus
- > Convenient local venues and affordable registration fees
- > Teams of local experts, comprised of physicians and advanced practice providers, providing an interdisciplinary team approach to treatment.
- > Participants can receive up to **6.0 AMA PRA Category 1 Credits™** or up to 7.1 nursing education credits

## WHO SHOULD ATTEND

This program is especially suited for **Hepatologists, Gastroenterologists, Internists, and Family Physicians, as well as related advanced practice providers, clinical pharmacists and nurse specialists.**

These are the providers who are primarily tasked with caring for PBC, PSC, NASH, Liver Cancer and complications of ESLD, both in the hospital and in the outpatient setting. The conference will primarily focus on the challenges of: Diagnosis, Natural history, Drug therapies, Side effect management, Hepatocellular carcinoma, Hepatic encephalopathy, Hyponatremia, Variceal bleeding and Hepatorenal syndrome.

FUTURE  
EVENTS

Seattle, WA	May 5
San Diego, CA	May 19
Detroit, MI	June 30

## SEMINAR SCHEDULE

7:30 am	<b>Registration, Continental Breakfast &amp; View Exhibits</b>
8:00 am	<b>Welcome and Pre-Test</b>
8:20 am	<b>End Stage Liver Disease: Treatment, Managing Complications and Transplant</b> <ul style="list-style-type: none"><li>• Staging, workup, and diagnosis of cirrhosis</li><li>• Medical care of the patient with end stage liver disease</li></ul> <b>Liver Transplantation</b> <ul style="list-style-type: none"><li>• Listing Criteria and MELD Exceptions</li></ul> <b>Case Study 1</b> – Cirrhosis and Encephalopathy
9:20 am	<b>Hepatocellular Carcinoma</b> <ul style="list-style-type: none"><li>• Screening diagnostic serum assays and imaging tests</li><li>• Diagnosis without histology</li><li>• Treatment and management options: Ablation, TACE and Surgery</li></ul>
10:00 am	<b>Break &amp; View Exhibits</b>
10:15 am	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"><li>• Current FDA-approved Therapies</li><li>• New chemotherapy regimens in development and testing</li><li>• Immunotherapy as the new MoA for HCC</li></ul> <b>Case Study 2</b> – Diagnosis and Treatment of Hepatocellular Carcinom
11:00 am	<b>Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"><li>• Epidemiology</li><li>• Ursodiol and Antibiotic Treatments</li><li>• Predicting Outcomes and Improving Survival</li></ul>
11:40 am	<b>New Treatments for Primary Biliary Cholangitis (PBC)</b> <ul style="list-style-type: none"><li>• Causes and Markers of PBC</li><li>• Treatment Management</li><li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li></ul> <b>Case Study 3</b> - PBC with inadequate response to Ursodiol
12:00 pm	<b>Lunch &amp; View Exhibits</b>
12:30 pm	<b>The Best Use of Non-Invasive Imaging for Fibrosis Assessment</b> <ul style="list-style-type: none"><li>• Technologies, Procedures and Outcomes</li></ul>
1:00 pm	<b>NAFLD, LAL-D and NASH</b> <ul style="list-style-type: none"><li>• Epidemiology and Demographics</li><li>• Diagnosis and Evaluation</li><li>• Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver</li><li>• Conventional treatments</li></ul>
1:45 pm	<b>Break &amp; View Exhibits</b>
2:00 pm	<b>NASH Treatments in Development</b> <ul style="list-style-type: none"><li>• Lifestyle Changes</li><li>• Drugs in Clinical development for NASH</li></ul> <b>Case Study 4</b> - NASH Diagnosis and Treatment
3:00 pm	<b>Post Test and Adjourn at 3:15pm</b>

## EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- > Speak to new treatments for liver disorders using evidence-based literature.
- > Review the current therapies and new treatment options for PBC.
- > Evaluate diagnostic tests for PSC, NASH and HCC that are in daily use soon, including newer non-invasive tools and procedures.
- > Discuss the therapeutic and management options for HCC: Ablation, TACE and Chemotherapies.
- > Identify the multiple causes for renal insufficiency in patients with ESLD including diuretic overuse, GI bleeding, systemic infection, hepatic decompensation, and hepatorenal syndromes type 1 and 2.
- > Discover why immunotherapy is the new Mechanism of Action for HCC.
- > Consider the benefits of therapeutic and lifestyle approaches to managing NAFLD and NASH patients.
- > Follow the guidelines for diagnosis and management of ascites in patients with ESLD including diuretics, therapeutic paracentesis, and transjugular intrahepatic portasystemic shunt (TIPS).
- > Solve detailed clinical studies based on the lessons presented in the seminar.

## COURSE DIRECTORS

### Paul Pockros, MD, FACC

Director, Liver Disease Center, Scripps Clinic  
Director, Clinical Research  
Scripps Translational Science Institute

### Catherine Fernet, MD,

Medical Director for Liver Transplantation  
Director, Center of Excellence for HCC  
Scripps Center for Organ and Cell Transplantation

## Registration Information

	Early Registration	Regular Registration
Physicians and Clinical Pharmacists	\$95	\$115
Nurses, Nurse Practitioners and PA's	\$70	\$90
Medical Residents & Fellows	\$60	\$80

### To Register & For More Information: <http://bit.ly/liver2018>

Or call: University of Louisville CME & PD (502) 852-5329

**Early Registration** ends Tuesday prior to program date.

**Regular Registration** begins Wednesday prior to through program date.

**Cancellation Policy** – Requests for cancellation must be submitted to [cmepd@louisville.edu](mailto:cmepd@louisville.edu) at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

## ACCREDITATION

### Joint Provider Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and SC Liver Research Consortium. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

### Designation Statement

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Nurses

This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1017. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

### Nurse Practitioners

AANP accepts Category I credit from **AMA PRA Category 1 Credit(s)<sup>TM</sup>** organizations accredited by ACCME.

### Physician Assistants

AAPA accepts Category I credit from **AMA PRA Category 1 Credit(s)<sup>TM</sup>** organizations accredited by ACCME.

## SPONSORS



UNIVERSITY OF LOUISVILLE  
CONTINUING MEDICAL EDUCATION & PROFESSIONAL DEVELOPMENT

The mission of the University of Louisville Continuing Medical Education and Professional Development program (CME & PD) is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>



Liver Research Consortium  
Your Link to a Successful Clinical Trial

The SC Liver Research Consortium (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research.

SCLRC's mission is to team research sponsors and SCLRC's over 80 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit [www.scliver.com](http://www.scliver.com)

## DISCLOSURE

### Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

### Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.

UNIVERSITY OF  
**LOUISVILLE**

CONTINUING MEDICAL  
EDUCATION & PROFESSIONAL  
DEVELOPMENT